Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 6 de 6
1.
Sci Transl Med ; 11(502)2019 07 24.
Article En | MEDLINE | ID: mdl-31341059

TYK2 is a nonreceptor tyrosine kinase involved in adaptive and innate immune responses. A deactivating coding variant has previously been shown to prevent receptor-stimulated activation of this kinase and provides high protection from several common autoimmune diseases but without immunodeficiency. An agent that recapitulates the phenotype of this deactivating coding variant may therefore represent an important advancement in the treatment of autoimmunity. BMS-986165 is a potent oral agent that similarly blocks receptor-stimulated activation of TYK2 allosterically and with high selectivity and potency afforded through optimized binding to a regulatory domain of the protein. Signaling and functional responses in human TH17, TH1, B cells, and myeloid cells integral to autoimmunity were blocked by BMS-986165, both in vitro and in vivo in a phase 1 clinical trial. BMS-986165 demonstrated robust efficacy, consistent with blockade of multiple autoimmune pathways, in murine models of lupus nephritis and inflammatory bowel disease, supporting its therapeutic potential for multiple immune-mediated diseases.


Autoimmunity/drug effects , Signal Transduction/drug effects , TYK2 Kinase/chemistry , Animals , Female , Healthy Volunteers , Heterocyclic Compounds/pharmacology , Humans , Interferon alpha-2/pharmacology , Mice , Mice, Inbred C57BL , Mice, SCID , Protein Kinase Inhibitors/pharmacology , TYK2 Kinase/antagonists & inhibitors
2.
J Invest Dermatol ; 138(7): 1518-1528, 2018 07.
Article En | MEDLINE | ID: mdl-29454560

Psoriasis is a chronic immune-mediated disease that represents a unique model for investigating inflammation at local and systemic levels. Bioactive lipid mediators (LMs) are potent compounds reported to play a role in the development and resolution of inflammation. Currently, it is not known to what extent these LMs are involved in psoriasis pathophysiology and related metabolic dysfunction. Here, we use targeted and untargeted liquid chromatography-tandem mass spectrometry approaches to quantify LMs in skin and peripheral blood from psoriasis patients and compared them with those of healthy individuals. Lesional psoriasis skin was abundant in arachidonic acid metabolites, as 8-, 12- and 15-hydroxyeicosatetraenoic acid, compared with adjacent nonlesional and skin from healthy individuals. Additionally, a linoleic acid-derived LM, 13-hydroxyoctadecadienoic acid, was significantly increased compared with healthy skin (607.9 ng/g vs. 5.4 ng/g, P = 0.001). These psoriasis skin differences were accompanied by plasma decreases in antioxidant markers, including glutathione, and impaired lipolysis characterized by lower concentrations of primary and secondary bile acids. In conclusion, our study shows that psoriasis skin and blood have disease-specific phenotype profiles of bioactive LMs represented by omega-6 fatty acid-oxidized derivatives. These findings provide insights into psoriasis pathophysiology that could potentially contribute to new biomarkers and therapeutics.


Fatty Acids, Omega-6/analysis , Lipid Metabolism , Psoriasis/metabolism , Skin/metabolism , Adult , Chromatography, High Pressure Liquid/methods , Fatty Acids, Omega-6/metabolism , Female , Healthy Volunteers , Humans , Male , Metabolomics/methods , Middle Aged , Psoriasis/blood , Psoriasis/pathology , Skin/pathology , Tandem Mass Spectrometry/methods
3.
JCI Insight ; 3(1)2018 01 11.
Article En | MEDLINE | ID: mdl-29321372

Inflammation is critical to atherogenesis. Psoriasis is a chronic inflammatory skin disease that accelerates atherosclerosis in humans and provides a compelling model to understand potential pathways linking these diseases. A murine model capturing the vascular and metabolic diseases in psoriasis would accelerate our understanding and provide a platform to test emerging therapies. We aimed to characterize a new murine model of skin inflammation (Rac1V12) from a cardiovascular standpoint to identify novel atherosclerotic signaling pathways modulated in chronic skin inflammation. The RacV12 psoriasis mouse resembled the human disease state, including presence of systemic inflammation, dyslipidemia, and cardiometabolic dysfunction. Psoriasis macrophages had a proatherosclerotic phenotype with increased lipid uptake and foam cell formation, and also showed a 6-fold increase in cholesterol crystal formation. We generated a triple-genetic K14-RacV12-/+/Srb1-/-/ApoER61H/H mouse and confirmed psoriasis accelerates atherogenesis (~7-fold increase). Finally, we noted a 60% reduction in superoxide dismutase 2 (SOD2) expression in human psoriasis macrophages. When SOD2 activity was restored in macrophages, their proatherogenic phenotype reversed. We demonstrate that the K14-RacV12 murine model captures the cardiometabolic dysfunction and accelerates vascular disease observed in chronic inflammation and that skin inflammation induces a proatherosclerotic macrophage phenotype with impaired SOD2 function, which associated with accelerated atherogenesis.


Atherosclerosis/immunology , Cholesterol/metabolism , Inflammation/immunology , Macrophages/metabolism , Psoriasis/immunology , Skin/immunology , Adolescent , Animals , Atherosclerosis/genetics , Cardiovascular Diseases/immunology , Child , Cytokines/metabolism , Disease Models, Animal , Dyslipidemias , Female , Foam Cells , Humans , Keratinocytes/metabolism , Male , Mice , Mice, Knockout , Multivariate Analysis , Neuropeptides/metabolism , Regression Analysis , Superoxide Dismutase/metabolism , rac1 GTP-Binding Protein/metabolism
4.
Arterioscler Thromb Vasc Biol ; 35(12): 2667-76, 2015 Dec.
Article En | MEDLINE | ID: mdl-26449753

OBJECTIVE: To understand whether directly measured psoriasis severity is associated with vascular inflammation assessed by (18)F-fluorodeoxyglucose positron emission tomography computed tomography. APPROACH: In-depth cardiovascular and metabolic phenotyping was performed in adult psoriasis patients (n=60) and controls (n=20). Psoriasis severity was measured using psoriasis area severity index. Vascular inflammation was measured using average aortic target-to-background ratio using (18)F-fluorodeoxyglucose positron emission tomography computed tomography. RESULTS: Both the psoriasis patients (28 men and 32 women, mean age 47 years) and controls (13 men and 7 women, mean age 41 years) were young with low cardiovascular risk. Psoriasis area severity index scores (median 5.4; interquartile range 2.8-8.3) were consistent with mild-to-moderate skin disease severity. Increasing psoriasis area severity index score was associated with an increase in aortic target-to-background ratio (ß=0.41, P=0.001), an association that changed little after adjustment for age, sex, and Framingham risk score. We observed evidence of increased neutrophil frequency (mean psoriasis, 3.7±1.2 versus 2.9±1.2; P=0.02) and activation by lower neutrophil surface CD16 and CD62L in blood. Serum levels of S100A8/A9 (745.1±53.3 versus 195.4±157.8 ng/mL; P<0.01) and neutrophil elastase-1 (43.0±2.4 versus 30.8±6.7 ng/mL; P<0.001) were elevated in psoriasis. Finally, S100A8/A9 protein was related to both psoriasis skin disease severity (ß=0.53; P=0.02) and vascular inflammation (ß=0.48; P=0.02). CONCLUSIONS: Psoriasis severity is associated with vascular inflammation beyond cardiovascular risk factors. Psoriasis increased neutrophil activation and neutrophil markers, and S100A8/A9 was related to both skin disease severity and vascular inflammation.


Aortitis/diagnosis , Fluorodeoxyglucose F18 , Multimodal Imaging/methods , Neutrophil Activation , Neutrophils/immunology , Positron-Emission Tomography , Psoriasis/diagnosis , Radiopharmaceuticals , Tomography, X-Ray Computed , Adult , Aortitis/blood , Aortitis/diagnostic imaging , Aortitis/immunology , Biomarkers/blood , Case-Control Studies , Female , Humans , Immunity, Innate , Inflammation Mediators/blood , Leukocyte Count , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Psoriasis/blood , Psoriasis/immunology , Severity of Illness Index
5.
Wilderness Environ Med ; 26(3): 335-42, 2015 Sep.
Article En | MEDLINE | ID: mdl-25937547

OBJECTIVE: The purpose of this study was to compare glucose and insulin responses during an oral glucose tolerance test (OGTT) in cold (C), neutral (N), and hot (H) environments. METHODS: Eleven males completed three 4-hour climate-controlled OGTT trials (C, 7.2°C; N, 22°C; and H, 43°C). Participants remained semireclined for 60 minutes before ingesting a 1.8 g/kg glucose beverage. Skin and rectal core temperatures were continuously monitored. Blood was collected just before glucose ingestion (time 0) and at 15, 30, 60, 90, 120, and 180 minutes, and analyzed for serum glucose, insulin, hematocrit, and hemoglobin. Expired gases were collected upon entering the chamber (-60 minutes), before glucose ingestion (0 minutes), and at 60, 120, and 180 minutes to determine V(O2) and respiratory exchange ratio. RESULTS: Rectal core temperature was greater in the H condition compared with both C and N (P < .001). Rectal core temperature was not different between C and N, whereas skin temperature was different across all trials (H greater than N greater than C). The V(O2) was greater in C than in both H and N during all time points. Carbohydrate oxidation was greater in C compared with H and N (P < 0.001). Glucose was higher during H compared with C and N (P ≤ 0.002). Glucose was elevated in C compared with N. Insulin was higher in H compared with C (P = 0.009). Area under the curve for serum glucose was greater in H compared with C and N (P ≤ 0.001); however, there was no significant difference in area under the curve for insulin. CONCLUSIONS: These data indicate that after an OGTT, glucose and insulin are elevated in a hot environment.


Blood Glucose/analysis , Body Temperature , Cold Temperature , Energy Metabolism , Hot Temperature , Insulin/metabolism , Glucose Tolerance Test , Humans , Male , Montana , Skin Temperature , Young Adult
...